Last reviewed · How we verify

NCT03976622: INFLAMMAVit

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata

Status unknown Last updated 6 June 2019
What this trial tests

trial testing Blood samples in Vitiligo in 450 participants. Status unknown.

Timeline
3 June 2019
Primary endpoint
3 June 2023
3 June 2023

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment450
Start date3 June 2019
Primary completion3 June 2023
Estimated completion3 June 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

Adults 18 to 75, any sex, with Vitiligo or Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood samples

Trials testing the same drug.

Other recruiting trials for Vitiligo

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03976622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing